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A B S T R A C T
Refractory status epilepticus (SE) is a current daily therapeutic challenge. Electroconvulsive therapy
(ECT), which is frequently used to treat psychiatric disorders, is known to raise the seizure threshold. As
such, ECT could be of major interest in refractory SE. In this paper, we provide a brief overview of ECT in
refractory SE. Although no placebo-controlled or open-label study has been published on the efﬁcacy or
safety of ECT in refractory SE, eight case reports have been identiﬁed. SE cessation was obtained in 80% of
cases, and complete recovery was achieved in 27% of patients. Despite the heterogeneity of the ECT
parameters used in these articles, we identiﬁed some common features that may be recommended for
the use of ECT in refractory SE. ECT might be a viable therapeutic strategy for the most resistant and
severe cases of SE, particularly after the failure of two inductions of anesthetic coma. This potential
indication highlights the urgent need for clinical trials that assess the usefulness of ECT in refractory SE.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Status epilepticus (SE) is characterized by either prolonged
epileptic seizure activity lasting at least 30 min or the occurrence
of recurrent seizures between which baseline neurological status is
not recovered. Although anticonvulsant treatments, such as
benzodiazepines, phenytoin, valproate or phenobarbital, are
remarkably efﬁcient in SE, pharmacological resistance is observed
in approximately 30% of patients.1 For resistant patients, second-
line treatments, including anesthetic drugs, such as propofol,
midazolam or pentobarbital, are usually required to suppress
seizures. Despite the availability of these efﬁcient treatments, SE
still shows a high mortality rate in adults, reaching up to 22%. This
is particularly true when SE is associated with a long duration, very
young or advanced age, encephalitic etiology or high morbidity.1–3
Therefore, refractory SE remains a daily challenge for which our
current therapeutic strategies fall short.
Electroconvulsive therapy (ECT) is a well-known treatment that
is used daily in several psychiatric disorders. It consists of applying* Corresponding author at: Institut des Maladies Neurode´ge´ne´ratives, CNRS UMR
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http://dx.doi.org/10.1016/j.seizure.2012.07.010electrical stimulation to the brain under mild anesthesia,
accompanied by an electrical ﬁt. ECT is markedly efﬁcient, safe
and may be life-saving for people who suffer from refractory mood
disorders or schizophrenia.4 The main side effect of ECT, objective
memory impairment, is generally reversible, although a small
proportion of ECT patients complain of persisting memory
difﬁculties following treatment.5,6 The use of ECT in refractory
epilepsy and SE is mentioned in psychiatry practice guidelines.7
However, this treatment is rarely used in daily practice and
remains poorly assessed in refractory SE. Only a few case reports
have discussed the efﬁcacy of ECT in refractory SE. Here, we
provide a brief overview of those case reports to highlight some
recommendations for the assessment and use of ECT in refractory
SE.
2. Materials and methods
The MEDLINE database was searched without limits on the year
of publication through February 2012 using the keyword
combination of ‘‘electroconvulsive therapy’’ and any of the
following terms: ‘‘status epilepticus’’, ‘‘intractable epilepsy’’,
‘‘refractory status epilepticus’’, ‘‘malignant status epilepticus’’,
‘‘epilepsy’’ and ‘‘seizure’’. Articles related to the cure of epilepsy
were excluded to focus this review speciﬁcally on status
epilepticus. All identiﬁed abstracts were read by two independentvier Ltd. All rights reserved.
V. Lambrecq et al. / Seizure 21 (2012) 661–664662investigators (VL and JYR) to select all relevant articles, reviews
and case reports. The reference lists of these papers were also
screened to optimize our bibliographic search.
3. Results
Neither double-blind nor open-label studies assessing ECT in
refractory SE were found. Eight case reports were identiﬁed,
including 11 patients with refractory SE treated by ECT. The results
from these case reports are summarized in Table 1. After the
clinical description of these reports, we will present the ECT
parameters used for each patient.
3.1. Case reports
Although ECT has been used to treat epilepsy since the 1930s,8,9
the ﬁrst case reports discussing the use of ECT in refractory SE were
published in the 1990s.Table 1
Efﬁcacy and safety of ECT in refractory status epilepticus.
Article Sex age Etiology Medication trials Interval
SE–ECT 
Viparelli and
Viparelli, 1992
, 19 Partial
epilepsy
PHT DZP NA 
Carrasco et
al., 1997
< 25 Head injury PHT CBZ DZP
PHB PBT
40 
Griesemer
et al., 1997
< 13 Partial
epilepsy
microgyria
PHB PHT ACT
CLZ VPA GBP
LTG FBM
30 
Recurrence 1
year later
NA NA 
Recurrence 8
months later
NA NA 
, 10 Partial
epilepsy
PHB PHT CBZ
VPA FBM GBP
LOR KD
NA 
Lisanby
et al., 2001
< 36 Partial
epilepsy
dysplasia
subdural
hematoma
TPM FBM CBZ
VPA PGB VGB
NZP PHB PHT
PBT PF MDZ
26 
Morales
et al., 2004
, 8 Ceroido-
lipofuscinose
ZNS PHB LEV KET NA 
Cline and
Ross, 2007
< 39 Viral
encephalitis
fosPHT VPA PBT LEV OXC
TPM LOR FBM
103 
Kamel
et al., 2010
, 32 Viral
encephalitis
VPA PHT PHB LEV TPM
PBT KT MDZ PF
30 
, 41 Viral
encephalitis
fosPHT LEV VPA PBT KT 30 
, 26 Viral
encephalitis
PHT VPA PBT LEV TPM
PHB IF KT MDZ
70 
Shin
et al., 2011
, 7 Polymicrogyria VPA LEV CLB LOR PHB MDZ
FEN TPM PBT KET KD steroid
14 
NA, not available; ACT, acetazolamine; CLB, clobazam; CLZ, clonazepam; DZM, diaze
isoﬂurane; KD, ketogenic diet; KT, ketamine; LTG, lamotrigine; LEV, levetiracetam; 
phenobarbital; PF, propofol; PGB, pregabalin; PHT, phenytoin; PBT, pentobarbital; SUD
sodium valproate; ZNS, zonisamide.Viparelli and Viparelli10 reported the case of a 19-year-old
woman with refractory continuing partial seizures (46 seizures in
12 h). Oral and intravenous phenytoin and diazepam failed to
result in recovery (Table 1). Her seizures were ﬁnally controlled
after two sessions of ECT 48 h apart. ECT was given with atropine
premedication, curare and diazepam. The ﬁrst ECT session resulted
in the reduction of seizure frequency to three seizures per day. The
second ECT session resulted in seizure cessation. Subsequent
seizure activity was controlled with anticonvulsant medication,
especially carbamazepine, for many years.
Carrasco-Gonzalez et al.11 described the ECT-related improve-
ment of post-traumatic SE in a 25-year-old man. After the failure of
treatment including phenytoin, carbamazepine, phenobarbital and
diazepam to control seizures, a pentobarbital coma was induced
(Table 1). After 40 days of coma, six sessions of ECT over two weeks
resulted in a complete recovery in the following month.
Griesemer et al.12 reported two children with intractable
seizure disorders secondary to cortical dysplasia. First, a(days)
Electrodes
placement
Charge
(mC)
ECT sessions Outcome
Bitemporal NA 2/3 days Cessation of seizure
activity and
recovering the
baseline neurological
status
NA NA 6/15 days Cessation of SE
Total recovery
Frontocentral 64–217 4/9 days Partial improvement
in seizure frequency
and severity
Frontocentral 201–302 3/3 days Cessation of SE
Reduction of seizures
Frontocentral 201–403 8/15 days Cessation of SE
Frontocentral 180–576 6/15 days Reduction of seizures
Right
frontotemporal
left parietal
1152–3379 5/5 days Cessation of seizures
Persistant coma
NA 192–1536 5/5 days Death
Bifrontotemporal 576 9/3 days Cessation of SE
Persistant seizures
Cognitive disorders
Bifrontotemporal 505 13/5 days Cessation of SE
Total recovery
Bifrontotemporal NA 4/day
during 5 days
Nosocomial
pneumonia
Acute renal failure
Death
Bifrontotemporal NA 8/10 days Cessation of SE
Reduction of seizures
Mild cognitive
disorders
Bitemporal NA 4/8 days Cessation of SE
Improvement of mental
status SUDEP six
months later
pam; CBZ, carbamazepine; FEN, fentanyl; FBM, felbamate; GBP, gabapentin; IF,
LOR, lorazepam; MDZ, midazolam; NZP, nitrazepam; OXC, oxcarbazepine; PHB,
EP, sudden unexpected death in epilepsy; TPM, topiramate; VGB, vigabatrin; VPA,
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tonic seizures over one month (for example, ten seizures during
the 18 h before ECT). After the failure of phenobarbital, phenytoin,
acetazolamide, clonazepam, valproate, gabapentin, lamotrigine
and felbamate, medical treatments were withdrawn and he was
treated with four sessions of ECT over nine days (Table 1). This
treatment was associated with a reduction in the intensity and
duration of seizure episodes. One year later, the child experienced
a new episode of non-convulsive SE (drop attacks every few
minutes). Three ECT sessions were then given over three days,
with demonstrated improvement over the next weeks character-
ized by the remission of tonic seizures and the occasional
recurrence of mild head drops. Following a third relapse, three
ECT sessions were given, with improvement observed from the
ﬁrst day of treatment. Three weeks later, a fourth ECT treatment
was necessary, again yielding immediate improvement. In the
second case report, the authors described a 10-year-old girl with
microcephaly and generalized tonic–clonic seizures. Initial
treatments with phenobarbital, phenytoin, carbamazepine,
valproate, gabapentin, felbamate and lorazepam were unsuccess-
ful, and a ketogenic diet was initiated. Only valproate and
gabapentin were continued, and three ECT sessions over ﬁve days
led to a marked improvement. For the second session, the dose of
valproate was reduced and gabapentin was withdrawn to use a
lower energy for inducing ECT seizures. Three additional sessions
over three days were performed following relapse two weeks
later, with demonstrated efﬁcacy.
Lisanby et al.13 reported on a 36-year-old man with a history of
treatment-resistant epilepsy secondary to bifrontal cortical
dysplasia. He suffered from non-convulsive SE secondary to
subdural hematoma, which had been treated by several combina-
tions of antiepileptic pharmacologics, including vigabatrin, phe-
nobarbital, nitrazepam, phenytoin, pentobarbital, propofol and
midazolam (Table 1). After 26 days of SE, severe medical
complications occurred, including disseminated intravascular
coagulopathy. ECT was then administered over ﬁve sessions,
which caused electroencephalographic epileptiform activity to
resolve. Pentobarbital was discontinued 24 h before the ﬁrst
session, and vigabatrin, phenobarbital, nitrazepam, phenytoin and
midazolam were maintained throughout ECT sessions. One month
after ECT treatment, SE remained in remission; however, the
patient did not regain consciousness and remained comatose.
Morales et al.14 reported the case of an 8-year-old girl with a
history of two prior episodes of SE secondary to ceroid
lipofuscinosis. After the failure of pharmacological treatments,
including lorazepam, fosphenytoin, oxcarbazepine, levetiracetam,
phenobarbital and lamotrigine, and the failure of repetitive
transcranial magnetic stimulation, she was referred for ECT
treatment (Table 1). ECT was administered concomitantly with
zonisamide, phenobarbital and levetiracetam in ﬁve sessions over
ﬁve days with no adverse effects. Under thiopental coma, ECT
provoked electroencephalographic but not clinical seizures. ECT
treatment failed to demonstrate any improvement. The authors
mentioned that the patient was ‘‘unlikely to respond to any
treatment because of the progressive and overwhelming nature’’ of
the disease.
Cline and Ross15 reported a 39-year-old man with SE, which
was presumed to be the result of viral encephalitis. Multiple
conventional therapeutic strategies, including fosphenytoin,
valproate sodium, pentobarbital, levetiracetam, phenytoin, oxcar-
bazepine, topiramate, lorazepam and felbamate, yielded no clinical
improvement. The initial ECT treatment was planned for the 103rd
day after the onset of seizures. Pharmacological treatments were
continued during ECT treatment. The ﬁrst ECT session provoked a
marked decrease in spike activity, and two more sessions in the
following days resulted in the termination of SE. The patient’sseizure activity gradually decreased for sixteen months after ECT,
although some focal seizures persisted sporadically and were
associated with cognitive decline.
Three cases were described by Kamel et al.,16 and ECT-related
improvement was obtained in two patients. The three patients
were admitted with SE consecutive to viral encephalitis. The ﬁrst
patient was a 32-year-old woman who had successively received
usual therapeutic strategies for SE, including propofol, midazolam,
prednisolone, pentobarbital and ketamine, with no improvement.
Three trials of pentobarbital were performed to achieve complete
burst suppression without efﬁcacy. ECT was started six weeks after
the onset of seizures, without anticonvulsant discontinuation.
Propofol and midazolam were given between sessions to maintain
burst suppression. Four sessions were performed over a period of
ﬁve days and led to clinical and electroencephalographic
improvement. She complained of short retrograde amnesia and
anterograde amnesia that disappeared after the remission of viral
encephalitis. The second patient was a 41-year-old woman. Similar
therapeutic strategies and the same protocol of four daily cycles of
ECT were performed thirty days after the onset of SE. However, ECT
alone was not efﬁcient in this case. The addition of pentobarbital
concomitant with ECT treatment led to electroencephalographic
suppression. Unfortunately, after several days of pentobarbital
infusions, multiple complications (nosocomial infection and renal
failure) occurred, and the patient died. The third patient was a 26-
year-old woman in whom ECT was performed two months after
the onset of SE according to the same protocol. Despite a
therapeutic strategy including pentobarbital-induced coma, keta-
mine, isoﬂurane and high doses of methylprednisolone, the ﬁrst
two ECT sessions failed to provoke a generalized electrographic
seizure. The third session succeeded after midazolam was
withdrawn. SE completely stopped after the eighth session of
ECT. Nonetheless, some seizures remained, resulting in mild
difﬁculties with short-term memory and concentration.
Shin et al.17 reported the case of a 7-year-old girl with non-
convulsive SE secondary to bilateral polymicrogyria who was
treated with valproate, levetiracetam and clobazam. Anesthetic
coma with burst suppression was obtained with a combination of
midazolam, pentobarbital, ketamine, topiramate and steroids. ECT
was started on the 14th day after the onset of seizures, during
which pharmacological treatments were continued, except for
pentobarbital and ketamine, and midazolam was exchanged with
ﬂumazenil prior to each session. The ﬁrst two ECT sessions were
performed on consecutive days and resulted in a cessation of non-
convulsive SE within 6 h of treatment. Two days later, non-
convulsive SE symptoms returned. Six more ECT sessions were
necessary over the course of the next week to deﬁnitively
terminate SE. This was achieved with generalized slowing and
bihemispheric periodic lateralized epileptiform discharges in EEG.
4. Discussion
After the failure of drug therapies, physical treatments may be
considered for refractory SE. In the last decades, many physical
treatments have been discussed for refractory SE, such as
transcranial magnetic stimulation, vagal nerve stimulation, deep
brain stimulation or cerebrospinal ﬂuid drainage. Up to date, ECT
remains the most – but still poorly – assessed physical
treatment.18,19 Our overview of case reports suggests that ECT
may be of interest in some refractory and severe cases of SE. In the
11 patients (7 adults and 4 children) with refractory SE treated
with ECT described in the literature, ECT prevented SE in 80% of
cases, although full functional recovery was described in only three
patients (27%). In these patients, ECT was delivered 30–40 days
after the onset of SE. In contrast, the occasional persistence of
seizures (four patients, 36%) or presence of minor cognitive
V. Lambrecq et al. / Seizure 21 (2012) 661–664664impairment (two patients, 18%) may be explained by either the
delayed use of ECT15,16 or the speciﬁc etiology of SE in these
instances, such as cortical dysplasia12,13 or ceroid lipofuscinosis.14
Three patients (27%) succumbed to death, although this was
essentially due to the occurrence of medical complications and not
directly related to the use of ECT.
Of practical importance is the concern that the ECT parameters
and protocols used in these articles were heterogeneous, although
some parameters were similar. First, although anti-epileptic drugs
were most often continued during ECT, this pharmacological
treatment could be adapted to promote ECT-induced seizures. For
example, treatments such as midazolam could be reduced or
stopped to reduce the seizure threshold. Consistent with this idea,
some authors have also proposed using ﬂumazenil 15 min before
each ECT session. Second, ECT sessions were generally adminis-
tered in the month following the onset of SE. It is difﬁcult to assess
the impact of the duration of uncontrolled SE on ECT efﬁcacy;
however, one can reasonably assume that ECT might be more
effective when administered at the earliest possible stage. For
example, the effectiveness of ECT might be improved when used in
the days immediately following the identiﬁcation of pharmaco-
logical resistance. Likewise, early treatment might reduce the risk
of SE complications. However, as described by Kamel et al.16 and
Shorvon and Ferlisi18 ECT has to be administered only in super-
refractory SE cases, especially after the failure of at least two trials
of anesthetic coma with the maintenance of prior antiepileptic
drugs. Third, the frequency of ECT reported in these studies was
commonly scheduled between two and four sessions a week until
clinical or electroencephalographic improvement, which was
generally achieved during the ﬁrst ten days of treatment. The
number of sessions and duration of ECT were individualized for
each patient according to the evolution of the clinical and
electroencephalographic assessments. In most cases, subsequent
pharmacological treatments were used to efﬁciently maintain SE
remission after ECT cessation. Finally, a range of different ECT
electrode placements were tried by the authors, of which the
common placements were bitemporal or bifrontocentral.
Concerning the physiopathology, the anti-epileptic effects of
ECT are based on increased GABAergic transmission and the
prolongation of the refractory period after a seizure.20 ECT raises
the seizure threshold by activating the inhibitory mechanisms
needed to abort a seizure. ECT has potent anti-convulsant
properties that are shared with the anti-convulsant drugs used
in the treatment and prophylaxis of bipolar disorder, one of the
main indicators for the use of ECT in psychiatry. For example, an
enhanced seizure threshold was observed in 21% of patients with
severe mood disorder after ECT.21 It has been proposed that ECT
can activate the inhibitory mechanisms required to abort a seizure
by inducing generalized seizure, especially by modulating
GABAergic transmission. However, ECT is also known to modulate
all mono-aminergic pathways. Regardless, the mechanism by
which ECT is effective against SE and mood disorders remains to be
elucidated.
In conclusion, 11 case reports have been published assessing
the safety and efﬁcacy of ECT in refractory status epilepticus.
This review of case reports succeeded in the identiﬁcation ofcommon ECT parameters used in this very speciﬁc indication of
refractory status epilepticus. Although based on a small number
of cases, our review suggested that electroconvulsive therapy
was effective for many patients with refractory status epilepti-
cus. Thus, beyond all a priori ideas, electroconvulsive therapy
could be considered in the treatment algorithm for refractory
status epilepticus, particularly after the failure of two inductions
of anesthetic coma. Improved neurological outcomes might be
achieved with protocols that include ECT after inducing a
barbiturate coma but before irreversible brain damage has
occurred. Therefore, to conﬁrm this conclusion, case reports and
open-label clinical trials on the use of electroconvulsive therapy
in this indication should be conducted.
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